We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+9.85%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$349M
AUM Growth
+$53.4M
Cap. Flow
+$36.4M
Cap. Flow %
10.41%
Top 10 Hldgs %
7.12%
Holding
478
New
39
Increased
273
Reduced
76
Closed
38

Top Buys

Rank Stock Value
1
OXLC
Oxford Lane Capital
OXLC
+$2.36M
2
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$1.99M
3
LRCX icon
Lam Research
LRCX
+$1.97M
4
IDXX icon
Idexx Laboratories
IDXX
+$1.96M
5
TKO icon
TKO Group
TKO
+$1.96M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$1.85M
2
KKR icon
KKR & Co
KKR
+$1.62M
3
UAL icon
United Airlines
UAL
+$1.62M
4
CBRE icon
CBRE Group
CBRE
+$1.61M
5
NU icon
Nu Holdings
NU
+$1.58M

Sector Composition

Rank Sector Weight
1 Financials 33.25%
2 Healthcare 17.27%
3 Technology 14.61%
4 Industrials 8.9%
5 Consumer Discretionary 5.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STOK icon
251
Stoke Therapeutics
STOK
$2.09B
$226K 0.06%
9,627
+1,672
+21% +$28.6K
PRTA icon
252
Prothena Corp
PRTA
$440M
$219K 0.06%
22,443
+3,896
+21% +$29.9K
MAZE
253
Maze Therapeutics
MAZE
$1.5B
$218K 0.06%
8,397
+1,457
+21% +$24.6K
TERN
254
DELISTED
Terns Pharmaceuticals
TERN
$217K 0.06%
28,953
+5,026
+21% +$32.1K
XERS icon
255
Xeris Biopharma Holdings
XERS
$1.45B
$210K 0.06%
25,744
+4,470
+21% +$29.7K
CRVS icon
256
Corvus Pharmaceuticals
CRVS
$1.14B
$198K 0.06%
26,837
+4,660
+21% +$23.9K
SION
257
Sionna Therapeutics
SION
$188M
$197K 0.06%
6,698
+1,163
+21% +$25.3K
MRUS
258
DELISTED
Merus
MRUS
$193K 0.06%
2,054
+356
+21% +$23.2K
TNGX icon
259
Tango Therapeutics
TNGX
$4.5B
$189K 0.05%
22,532
+3,912
+21% +$26.5K
CYTK icon
260
Cytokinetics
CYTK
$10.4B
$188K 0.05%
3,428
+596
+21% +$24.6K
ARLP icon
261
Alliance Resource Partners
ARLP
$3.18B
$188K 0.05%
7,420
+819
+12% +$20.5K
EXE
262
Expand Energy Corp
EXE
$22.1B
$187K 0.05%
1,757
+351
+25% +$35.2K
MBX
263
MBX Biosciences
MBX
$3.19B
$186K 0.05%
10,614
+1,842
+21% +$24.6K
UPB
264
Upstream Bio Inc
UPB
$400M
$185K 0.05%
9,843
+1,709
+21% +$26.6K
DFTX
265
Definium Therapeutics
DFTX
$5.94B
$184K 0.05%
15,587
+2,706
+21% +$25.2K
EYPT icon
266
EyePoint Inc
EYPT
$1.16B
$183K 0.05%
12,843
+2,230
+21% +$25.7K
BIP icon
267
Brookfield Infrastructure Partners
BIP
$17.7B
$182K 0.05%
5,530
+256
+5% +$8.06K
EVRG icon
268
Evergy
EVRG
$19.1B
$182K 0.05%
2,391
-162
-6% -$11.5K
ABCL icon
269
AbCellera Biologics
ABCL
$2.85B
$182K 0.05%
36,123
+6,271
+21% +$27.6K
GPRK icon
270
GeoPark
GPRK
$631M
$181K 0.05%
28,491
+5,118
+22% +$33.7K
AEP icon
271
American Electric Power
AEP
$67.1B
$181K 0.05%
1,613
-73
-4% -$7.99K
LNT icon
272
Alliant Energy
LNT
$17.8B
$181K 0.05%
2,689
-145
-5% -$9.36K
MUR icon
273
Murphy Oil
MUR
$5B
$181K 0.05%
6,373
-536
-8% -$13.5K
ETR icon
274
Entergy
ETR
$49.5B
$180K 0.05%
1,935
-184
-9% -$16.2K
CQP icon
275
Cheniere Energy
CQP
$31.7B
$180K 0.05%
3,348
+284
+9% +$15.4K
9 10
11
12 13

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q3 2025 Portfolio in Review

As of Q3 2025, Virtus Investment Advisers held 478 positions worth $349M, up 18% from $296M the previous quarter. Its ten largest holdings account for 7.1% of the portfolio.

Virtus Investment Advisers deployed $36.4M of net new capital in Q3 2025, opening 39 new positions and adding to 273 existing holdings. Its largest new stake was Oxford Lane Capital: 129,209 shares worth $2.19M.

By sector, the portfolio is most concentrated in Financials at 33% of assets, up from 33% a quarter earlier, followed by Healthcare and Technology.

On the sell side, the largest reduction was Incyte, an estimated $1.85M trimmed.

  • Virtus Investment Advisers's largest Q3 2025 buy was Oxford Lane Capital: 129,209 shares worth $2.19M.
  • Virtus Investment Advisers added most to Prospect Capital in Q3 2025, an estimated $697K increase.
  • Virtus Investment Advisers's biggest Q3 2025 reduction was Incyte, cutting an estimated $1.85M.
  • Virtus Investment Advisers fully exited KKR & Co in Q3 2025, selling an estimated $1.62M.
  • Virtus Investment Advisers's ten largest holdings make up 7.1% of its $349M portfolio in Q3 2025.
  • Virtus Investment Advisers opened 39 new positions and closed 38 in Q3 2025.
  • Virtus Investment Advisers's portfolio value rose 18% quarter-over-quarter to $349M.

Based on Virtus Investment Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.